Company Overview
Avvinity Therapeutics Limited is a Dissolved Private Limited Company.
Registered Address

10 Lower Thames Street, London, EC3R 6AF
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameAVVINITY THERAPEUTICS LIMITED
Company Number09967702
Registered Office Address10 Lower Thames Street
 EC3R 6AF
Company CategoryPrivate Limited Company
Company StatusDissolved
Country of OriginUnited Kingdom
Incorporation Date25/01/2016
Accounting Reference Date Day31
Accounting Reference Date Month12
Accounts Next Due Date30/09/2023
Accounts Last Made Up Date31/12/2021
Accounts Account CategoryTOTAL EXEMPTION FULL
Returns Next Due Date22/02/2017
Previous Company NameChanged Date
CENTAURI ONCOLOGY LIMITED03 Mar 2016
Directors & Members
Show Resigned
Nicolas Higgins - Director
(British, 70 years old, born September 1956)
Appointed 04 July 2016
 Active
Christopher Lowe - Director
(British, 51 years old, born July 1975)
Appointed 13 February 2019
 Active
Jonathan Moore - Director
(British, 59 years old, born April 1967)
Appointed 01 November 2020
 Active
Nicholas Staples - Director
(British, 56 years old, born February 1970)
Appointed 01 November 2020
 Active
Jonathan Synett - Director
(British, 49 years old, born April 1977)
Appointed 21 July 2020
 Active
Clare Terlouw - Director
(British,Canadian, 53 years old, born December 1973)
Appointed 04 June 2021
 Active
Michael Westby - Director
(British, 60 years old, born June 1966)
Appointed 25 January 2016
 Active
Secretaries
No Secretaries Appointed
Other Company Directorships
Nicolas Higgins
No companies found
Christopher Lowe
HORIZON DIAGNOSTICS LIMITED
HORIZON DISCOVERY BIOSCIENCES LIMITED
HORIZON DISCOVERY GROUP LIMITED
REVVITY DISCOVERY LIMITED
SYNTHETX LIMITED
Jonathan Moore
EPITOPEA LIMITED
JDM LIFE SCIENCES LIMITED
OUTFOX BIO LIMITED
PENCIL BIOSCIENCES LIMITED
Nicholas Staples
AMBERJACK CONSULTING LIMITED
LOCATE BIO LIMITED
Jonathan Synett
AMPERSAND HEALTH LIMITED
AZADYNE LTD
BMBW LTD
BOWTHORPE GROWTH PARTNERS LTD
BOWTHORPE INVESTMENT GROUP LTD
BOWTHORPE PROPERTY INVESTMENTS LTD
BPI SPV ALTON LTD
COS HOLDINGS LTD
CURESPONSE UK LTD
EMTEQ LIMITED
HABONIM DROR
HEALTHTECH SPECIAL OPPORTUNITIES PLC
KENT LIFE SCIENCE (GP) LLP
KENT LIFE SCIENCE (SLP) LIMITED
LUCKY PADEL LTD
NCL TECHNOLOGY VENTURES LTD
SLACO PROJECTS LTD
Clare Terlouw
BIOINDUSTRY ASSOCIATION
CET CONSULTING LTD
CLOSED LOOP MEDICINE LTD
CUMULUS NEUROSCIENCE LIMITED
DJS ANTIBODIES LTD
DUCENTIS BIOTHERAPEUTICS LTD.
ENSOCELL LTD
ERPIN BIO LIMITED
RQ BIOTECHNOLOGY HOLDINGS LIMITED
RQ BIOTECHNOLOGY LIMITED
RQBIO COVID LIMITED
STEVENAGE BIOSCIENCE CATALYST
Michael Westby
AGALIMMUNE LTD.
CENTAURI THERAPEUTICS LIMITED
COS HOLDINGS LTD
IMOPHORON LIMITED
RQ BIOTECHNOLOGY HOLDINGS LIMITED
RQ BIOTECHNOLOGY LIMITED
Balance Sheet Unlock full report
Accounts Date 31-Dec-2021 31-Dec-2020 31-Dec-2019
Balance Sheet
Fixed Assets 3,044 3,577 0
Current Assets 1,764,045 2,837,217 795,508
Creditors Due Within One Year 152,662 181,616 64,004
Working Cap 1,611,383 2,655,601 731,504
Total Assets Less Current Liabilities 1,614,427 2,659,178 731,504
Long-term Liabilities 3,242,575 3,102,575 0
Net Assets -1,628,148 -443,397 731,504
Share Capital & Reserves
Share Cap - - -
Profit & Loss Reserves - - -
Other Reserves - - -
Shareholders Funds -1,628,148 -443,397 731,504
Common Size Financial Analysis Unlock full report
Accounts Date 31-Dec-2021 31-Dec-2020 31-Dec-2019
Tangible Fixed Assets - - -
Fixed Assets 0.2% 0.1% 0.0%
Stocks Inventory - - -
Debtors 15.0% 7.0% 40.2%
Cash Bank In Hand 84.8% 92.8% 59.8%
Current Assets 99.8% 99.9% 100.0%
Creditors Due Within One Year 8.6% 6.4% 8.0%
Net Current Assets Liabilities 91.2% 93.5% 92.0%
Creditors Due After One Year - - -
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability - - -
Called Up Share Capital - - -
Share Capital Allotted Called Up Paid - - -
Profit Loss Account Reserve - - -
Shareholder Funds -92.1% -15.6% 92.0%
Capital Employed - - -
Total Assets Less Current Liabilities 91.4% 93.6% 92.0%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Dec-2021 31-Dec-2020 31-Dec-2019
Liquidity Ratio 11.6 15.6 12.4
Solvency Ratio 0.5 0.9 12.4
Reserves to Assets - - -
Secured Creditors Unlock full report
Mortgages Charges 0
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 0
Assets and Debt Analysis Unlock full report
Accounts Date 31-Dec-2021 31-Dec-2020 31-Dec-2019
Assets 1,767,089 2,840,794 795,508
Debt 3,395,237 3,284,191 64,004
Net Assets/Debt -1,628,148 -443,397 731,504
Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around EC3R 6AF
MASSIVE INTERACTIVE MEDIA LIMITED
6TH FLOOR, 55, NEW OXFORD STREET, LONDON, EC3R 6AF
Document Filings
Final Gazette dissolved following liquidation
Return of final meeting in a creditors' voluntary winding up
Registered office address changed from 66 Prescot Street Prescot Street London E1 8NN to 10 Lower Thames Street London EC3R 6AF on 31 December 2023
Liquidators' statement of receipts and payments to 5 September 2023
Appointment of a voluntary liquidator
Resolutions
Statement of affairs
Registered office address changed from First Floor 5 Fleet Place London EC4M 7rd United Kingdom to 66 Prescot Street Prescot Street London E1 8NN on 12 September 2022
Statement of capital following an allotment of shares on 19 April 2022
Change of details for Cos Holdings Ltd as a person with significant control on 11 March 2022
Director's details changed for Christopher Eric Lowe on 10 March 2022
Registered office address changed from First Floor Thavies Inn House 3-4 Holborn Circus London EC1N 2HA to First Floor 5 Fleet Place London EC4M 7rd on 10 March 2022
Confirmation statement made on 24 January 2022 with updates
Current accounting period shortened from 31 July 2022 to 31 December 2021
Current accounting period shortened from 31 December 2021 to 31 July 2021
Appointment of Clare Elizabeth Terlouw as a director on 4 June 2021
Termination of appointment of Pauline Christine Stasiak as a director on 28 May 2021
Cessation of Centauri Therapeutics Limited as a person with significant control on 13 May 2021
Notification of Cos Holdings Ltd as a person with significant control on 13 May 2021
Confirmation statement made on 24 January 2021 with updates
Appointment of Dr Jonathan David Moore as a director on 1 November 2020
Appointment of Mr Nicholas James Staples as a director on 1 November 2020
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2026 Check Free